Sign In
By signing in or creating an account, you agree with Associated Broadcasting Company's Terms & Conditions and Privacy Policy.
By signing in or creating an account, you agree with Associated Broadcasting Company's Terms & Conditions and Privacy Policy.
New Delhi: The shares of drug major Cipla will be in focus on July 28, 2025, Monday after the drug major declared its Q1 2025-26 Results. The company posted a 10 per cent rise in its consolidated profit after tax to Rs 1,298 crore in the April-June quarter this fiscal, while it stood at Rs 1,178 crore in the first quarter of the previous fiscal.
The increase in PAT 2025 was a result of robust sales growth in India, Europe, and Africa.
Cipla shares settled 2.95 per cent up at Rs 1,535 apiece. Details on BSE:
In its quarter ending June 2025, the drug manufacturer mentioned that its total Income from operations increased to Rs 6,957 crore, as against Rs 6,694 crore in the same period a year ago.
The company's One-India business recorded a growth of 6 per cent year-on-year during the first quarter of 2025-26, Cipla MD and Global CEO Umang Vohra said.
“Key therapies in the branded prescription business continued to outpace the market growth, trade generics business growth trajectory is back on track and anchor brands of consumer health business maintained leadership position,” Vohra stated.
"Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front," he added.
The sales in the Indian market increased to Rs 3,070 crore in the April-June quarter, an increase of 6 per cent as compared with Rs 2,898 crore in the Q1 of 2024-25.
The drug major’s North America sales recorded a slump of 7 per cent year-on-year to Rs 1,933 crore for the June quarter.
Data from the emerging markets and Europe recorded 11 per cent growth in sales to Rs 861 crore for the Q1 of FY26, while it stood at Rs 779 crore in the year-ago period.
Africa sales recorded a growth of 14 per cent year-on-year to Rs 871 crore for the Q1 of FY26 as compared with Rs 766 crore in the first quarter of last year.
The paid-up equity share capital stands increased to Rs 161.55 crore (80,77,51,221 equity shares of face value Rs 2 each) upon allotment of 1,04,948 equity shares and 29,153 equity shares of Rs 2 each pursuant to "ESOS 2013-A" and "Cipla ESAR Scheme 2021" respectively during the quarter ended 30th June, 2025, the statement from the company read.
(Disclaimer: (Disclaimer: This article is only meant to provide information. TV9 does not recommend buying or selling shares or subscriptions of any IPO, Mutual Funds, gold and crypto assets.))
